Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production
Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today the peer-reviewed publication of, “A novel role for the adenovirus L4 region 22K and 33K proteins in adeno-associated virus production,” in the research journal Human Gene Therapy. The article was authored by a team of molecular development scientists at Forge led by David Dismuke, Ph.D., Chief Technical Officer, Linas Padegimas, Ph.D., Molecular Development Senior Director, and Angela Adsero, Ph.D., Molecular Development Scientist II.
Specific adenoviral genes are required for AAV production. However, a novel, undiscovered gene in particular has been overlooked because of its shared DNA sequence with a gene regulatory region that determines when or how much protein is made from a gene. By using molecular techniques to decouple the dual-purpose nature of this sequence, the Forge scientific team demonstrated that the L4 region 22K protein is an additional requirement for AAV vector production that had previously gone unnoticed. The study also suggests that the L4 region 33K protein is important for increasing AAV production.
“Forge is committed to improving gene therapy manufacturing through scientific innovation. The discovery of these vital AAV production requirements provide the potential for a more targeted and efficient production strategy, while also strengthening our IP portfolio,” said David Dismuke, Ph.D., Chief Technical Officer at Forge. “I am exceptionally proud of the Forge team for their hard work in contributing to our understanding of the essential elements of AAV production so that we can keep advancing the field of gene therapy.”
The article’s lead author was Angela Adsero, Ph.D. Contributing authors include the following Forge molecular development scientists: Brendan Chestnut, M.Sc., Sara Shahnejat-Bushehri, Ph.D., Lalita Sasnoor, Ph.D., Travis McMurphy, Ph.D., Michael Swenor, Ryan Pasquino, Arun Pradhan, Ph.D., Victor Hernandez, Ph.D., Linas Padegimas, Ph.D., and David Dismuke, Ph.D. The full research article can be accessed and will be available through open access here: https://www.liebertpub.com/doi/10.1089/hum.2023.146.
“This interesting finding may significantly impact gene therapy manufacturing and that translates to improved and potentially life-transforming genetic medicines for millions of patients suffering from genetic diseases worldwide,” said Robert Kotin, Ph.D., a leading voice in AAV and gene therapy manufacturing and a member of Forge’s Scientific and Manufacturing Advisory Board. “The Forge team has deep roots in developing genetic medicines and in vector manufacturing, as evidenced by these findings.”
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company focused on enabling access to life-changing gene therapies. Forge was founded in 2020 and is headquartered in the cell and gene therapy hub of Columbus, Ohio. Its 200,000 square foot facility, the Hearth, is dedicated to AAV manufacturing with 20 custom-designed cGMP suites. Offerings include scalable, end-to-end manufacturing services including process and analytical development, cGMP viral vector manufacturing, final fill, plasmid DNA manufacturing, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. Forge aims to accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212121940/en/
Contact information
Media Inquiries
Marina Corleto
Associate Director, Marketing and Communications
media@forgebiologics.com
Client Development
Taleen Barsoumian
Vice President, Client Development
CD@forgebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Fintech Company iCard Achieves Secure Customer Verification in Under 60 Seconds with Regula’s Solutions7.5.2025 09:00:00 EEST | Press release
iCard, a leading European e-money institution, has successfully upgraded its customer checks with Regula’s advanced biometric and document verification technologies. By integrating Regula Face SDK and Regula Document Reader SDK with its KYC (Know Your Customer) and risk assessment systems, iCard has moved to speedy, automated verification with improved fraud detection, and enhanced the overall experience for customers in 30+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506829598/en/ iCard streamlines onboarding and boosts fraud prevention by integrating Regula’s document and biometric verification technologies (Graphic: Regula) As a licensed fintech organization, iCard must comply with strict European KYC regulations while maintaining a robust risk assessment system alongside low-effort customer experience. Prior to implementing Regula’s solutions, manual verification processes led to inefficiencies, longer w
IFF Reports First Quarter 2025 Results6.5.2025 23:35:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2025. Management Commentary “IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business,” said IFF CEO Erik Fyrwald. “Our growth, combined with ongoing productivity initiatives, contributed to a meaningful increase in profitability. We also successfully completed the divestiture of our Pharma Solutions business two months ahead of schedule, a key milestone that supports the achievement of our targeted debt leverage ratio." “As we navigate the heightened macroeconomic uncertainty in today’s environment, we remain focused on what we can control - collaborating with our customers to drive growth, investing in innovation and delivering increased productivity. We are maintaining our full-year financial guidance ranges but recognize that the uncertain environment has potential for more challenges, yet we remain confident in our long-term strategy
Lattice to Showcase Advanced Edge AI Solutions at New-Tech 2025 Exhibition6.5.2025 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it will showcase its latest FPGA technology at the New-Tech 2025 Exhibition. Lattice technology demos will be featured in the Telsys Ltd. booth, showcasing industry-leading low power, small form factor FPGAs and application-specific solutions enabling advanced embedded vision, artificial intelligence, and sensor fusion capabilities. Additionally, Lattice will deliver a technical presentation titled “Power-Efficient Robotics and Automation Fueled by Lattice FPGA Technology” about how advanced, power-optimized FPGAs can dramatically reduce power consumption for next-generation automation and robotics solutions for Industrial applications. Who: Lattice Semiconductor What / When: May 20 – 21: Lattice demo showcase (Telsys Ltd. Booth #67-68) May 21, 10:20 a.m.: “Power-Efficient Robotics and Automation Fueled by Lattice Semiconductor FPGA Technology” technical presentation Where: New-Tech 2025 Exhib
Rockstar Games Releases Trailer 2 for Grand Theft Auto VI6.5.2025 19:37:00 EEST | Press release
Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is proud to announce the release of Trailer 2 for Grand Theft Auto VI, alongside a closer look at the biggest, most immersive evolution of the series yet: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506495901/en/ Set to launch on May 26, 2026, on PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems, Grand Theft Auto VI will soon be available for wishlisting on both the PlayStation and Microsoft Stores. Vice City, USA. Jason and Lucia have always known the deck is stacked against them. But when an easy score goes wrong, they find themselves on the darkest side of the sunniest place in America, in the middle of a criminal conspiracy stretching across the state of Leonida — forced to rely on each other more than ever if they want to make it out alive. Further details can be found at www.r
Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Market Lending Joint Venture6.5.2025 17:07:00 EEST | Press release
Monroe Capital, Sumitomo Mitsui Banking Corporation (SMBC) and MA Asset Management (part of MA Financial Group, ASX: MAF) today announced the formation of a new joint venture (“JV”), which will invest up to US$1.7 billion in senior secured loans to U.S. middle market borrowers. The JV harnesses the complementary capabilities of the three partnering institutions to establish a differentiated platform focused on the attractive middle market subset of private credit. The JV expects to benefit from broad access to high-quality, proprietary deal flow of first-lien senior-secured loans to established middle market companies, leveraging the loan origination capabilities of Monroe Capital’s direct lending infrastructure, SMBC’s established private credit and sponsor finance platform and MA Financial’s expertise in specialty credit and co-lending. The JV’s investable capital will be provided by Monroe Capital, SMBC and MA Financial (via its managed funds). Monroe Capital is one of the largest l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom